Ftse Mib
35.366,20
0,61%
DAX
18.869,36
0,78%
S&P 500
5.308,15
1,17%
NASDAQ
16.742,39
1,40%
Bitcoin
66.348,18
0,13%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ AN2 Therapeutics Inc (ANTX) AN2 Therapeutics Inc (ANTX) Notizie

ANTX

AN2 Therapeutics (ANTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ANTX
DataOraFonteTitoloSimboloCompagnia
14/05/202422:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANTXAN2 Therapeutics Inc
14/05/202422:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
14/05/202422:01Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:ANTXAN2 Therapeutics Inc
14/05/202422:01Business WireAN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
28/03/202421:10Business WireAN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
13/02/202423:11Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANTXAN2 Therapeutics Inc
12/02/202412:45Business WireAN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
30/01/202422:10Business WireAN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences ConferenceNASDAQ:ANTXAN2 Therapeutics Inc
19/01/202400:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
02/01/202422:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
09/11/202322:05Business WireAN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
06/11/202313:00Business WireAN2 Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ANTXAN2 Therapeutics Inc
18/10/202313:00Business WireAN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
11/10/202306:01Business WireAN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023NASDAQ:ANTXAN2 Therapeutics Inc
26/09/202313:00Business WireAN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and MalariaNASDAQ:ANTXAN2 Therapeutics Inc
13/09/202313:00Business WireAN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
16/08/202322:50Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ANTXAN2 Therapeutics Inc
16/08/202304:42Business WireAN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common StockNASDAQ:ANTXAN2 Therapeutics Inc
10/08/202322:10Business WireAN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
09/06/202322:14Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ANTXAN2 Therapeutics Inc
25/05/202322:10Business WireAN2 Therapeutics to Present at Jefferies Healthcare ConferenceNASDAQ:ANTXAN2 Therapeutics Inc
11/05/202322:23Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ANTXAN2 Therapeutics Inc
11/05/202322:10Business WireAN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
01/05/202313:00Business WireAN2 Therapeutics to Present at JMP Securities Life Sciences ConferenceNASDAQ:ANTXAN2 Therapeutics Inc
26/04/202322:26Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ANTXAN2 Therapeutics Inc
26/04/202322:16Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:ANTXAN2 Therapeutics Inc
26/04/202322:08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ANTXAN2 Therapeutics Inc
14/04/202312:07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ANTXAN2 Therapeutics Inc
06/04/202323:08Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:ANTXAN2 Therapeutics Inc
30/03/202312:08Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:ANTXAN2 Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ANTX

La tua Cronologia

LSE
BN31
Citi Fun 24
NASDAQ
RELY
Remitly Global
ASX
NSCG
NAOS Small Cap Opportuni...
BIT
P12A75
BNP PARIBAS ISSUANCE
USOTC
SCNQY
Societatea Nationala de ... (PK)
BOV
FSRF11
Fundo Invests Setoriais ...
COIN
ULTRAEUR
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network